About this trial
This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.
Eligibility criteria
Qualifiers
Age ≥18 years;
Patients presenting with posterior circulation ischemic stroke symptoms due to BAO;
BAO confirmed by computed tomographic angiography (CTA)/ magnetic resonance angiography (MRA);
Time from AIS symptom onset to randomization within 4.5-24 hours, stroke onset is defined as the onset of acute symptoms leading to the clinical diagnosis of basilar artery occlusion (BAO) not considering the time of any preceding minor prodromal symptoms (such as isolated vertigo, diplopia or sensory changes) as onset time or, if not known, the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);
Disqualifiers
Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) < 6 on computed tomography (CT)/CTA-Source Images/MRI with diffusion-weighted imaging (DWI)
CT/MR shows evidence of intracranial hemorrhage and tumor (except small meningioma)
Complete cerebellar infarct on CT/MRI with significant mass effect and compression of the 4th ventricle
Bilateral extensive brainstem infarction on CT/MRI
Trial design
Treatments tested in this trial
- Tenecteplase thrombolysis